Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues.
AI responses may include mistakes. For financial advice, consult a professional. Learn more
Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 .
Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook
Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion .
Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds.
Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ).
Mylan Stock Buy Or Sell -
Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues.
AI responses may include mistakes. For financial advice, consult a professional. Learn more mylan stock buy or sell
Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 . Analysts are concerned about a lack of a
Technical analysis indicates a recent "sell signal" from a pivot top point reached in late April 2026. Financial Health & Outlook Learn more Discounted Cash Flow (DCF) models suggest
Management expects roughly 2% total revenue growth and strong free cash flow exceeding $2.5 billion .
Viatris is currently viewed as a value play or income stock rather than a high-growth candidate. Its low valuation and steady dividends may make it a "buy" for long-term holders, while short-term traders might "hold" or "sell" due to flat price targets and operational headwinds.
Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ).